ASCO GU | sciencenewsnet.in

Breaking News

Webb Captures Top of Iconic Horsehead Nebula in Unprecedented Detail

Study Reveals Hiring Bias Against Former Business Owners

T. rex not as smart as previously claimed, scientists find

Probing the effects of interplanetary space on asteroid Ryugu

After 25 Years, Researchers Uncover Genetic Cause of Rare Neurological Disease

Cardio-fitness cuts death and disease by nearly 20%

Welcome to a world where we can cure blindness, chronic pain and neurological diseases with 3D printed surgical implants

Scientists suggested a new method for diagnosising of heart diseases

Scientists have mathematically simulated an epileptic seizure for the first time

Three Johns Hopkins Medicine Researchers Named Fellows of the American Association for the Advancement of Science

29 Apr, 2024

Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma — With Much Faster Treatment Time

January 27, 2024 sarah JonasResearch Results

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California.